Ethical issues: The multi-centre low-risk ethics/governance review process and AMOSS

Author
Vaughan, Geraldine, Pollock, Wendy, J. Peek, Michael, Knight, Marian, Ellwood, David, S. Homer, Caroline, Pulver, Lisa Jackson, McLintock, Claire, T. Ho, Maria, A. Sullivan, Elizabeth

Published
2012

Journal Title
Australian and New Zealand Journal of Obstetrics and Gynaecology

DOI
https://doi.org/10.1111/j.1479-828X.2011.01390.x

Copyright Statement
Copyright 2012 Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Published by Blackwell Publishing Ltd. This is the author-manuscript version of the paper. Reproduced in accordance with the copyright policy of the publisher. The definitive version is available at http://onlinelibrary.wiley.com/

Downloaded from
http://hdl.handle.net/10072/52988
Ethical Issues: The Multi-Centre Low-Risk Ethics/Governance Review Process and AMOSS

Abstract

Objective: To describe the ethics/governance review pathway undertaken by the Australasian Maternity Outcomes Surveillance System (AMOSS), a multi-centre population health study with minimal ethical impact.

Method: Prospective, descriptive study during 2009-11 of the governance/ethical review processes and associated workload to gain approval for Australian and New Zealand (NZ) maternity units with more than 50 births per year (n=303) to participate in AMOSS.

Results: Review processes ranged from a single application for 24 NZ sites, a single application for eligible hospitals in two Australian states, full Health Research Ethics Committee (HREC) applications for individual hospitals, through to simple letters of support. As of May 2011, 43 full/expedited ethics applications, 135 site governance applications and 139 letters of support requests were made over 26 months, involving an estimated 3,226 hours by AMOSS staff/investigators, and an associated resource burden by participating sites, to obtain approval to receive non-identifiable data from 285 hospitals.

Conclusion: The research that AMOSS conducts is critical for identifying the incidence of conditions that cause rare and serious maternal morbidity. Yet the highly variable ethical approval processes required to implement this bi-national study have been excessively repetitive and burdensome. The nature of this process jeopardises timely, efficient research project implementation, without corresponding benefits to research participants. The resource burden to establish research governance for a national surveillance of severe maternal morbidity in ANZ confirms the urgent need for the Harmonisation of Multi-centre Ethical Review (HoMER) to further streamline ethics/ governance review processes for multi-centre research.

Keywords: Ethical review; ethics committees, multi-centre studies; research governance, epidemiological studies.
Introduction
The challenge to efficient implementation of ethics/governance review processes for low-risk research conducted on multiple sites has long been recognised. In 2006, the Australian National Health and Medical Research Council (NHMRC) facilitated the development of a national single ethical review process for collaborative multi-centre studies: the HoMER initiative(1). The objectives of HoMER include the elimination of unnecessary duplication and delays in ethics reviews while promoting ethically sound research(2).

Whilst there has been much discussion about ethical reviews since the implementation of HoMER, the application process remains challenging to researchers and clinicians.(3-8) This paper describes the experience of one study across Australia and New Zealand (ANZ). The Australasian Maternity Outcomes Surveillance System (AMOSS) project is significant because of the volume and range of sites involved. The aim of this study was to examine the approval processes and workload required to implement AMOSS.

Methods
A prospective, descriptive study examined the ethical review and research governance processes required to obtain approval for AMOSS data collection throughout ANZ and the associated burden of this process.

Study setting: the AMOSS project
AMOSS studies the epidemiology of serious conditions of pregnancy. Maternal mortality is rare in Australasia, and there is a paucity of data available on the incidence, risk factors and outcomes of severe morbidity in pregnancy.

AMOSS is developing a bi-national perspective on these conditions and associated interventions. It provides an invaluable nexus of researchers, clinicians and a research infrastructure supported by over 300 ANZ maternity units. The research describes the burden of rare, severe events in pregnancy and raises awareness of perinatal morbidity. Findings will provide the incidence of severe maternal morbidity on specified conditions for the first time in ANZ, with no reliable data available from routine data sources(9). Additionally, AMOSS will develop an evidence base to inform clinical guidelines for relevant maternity services(10). Eligible maternity units contribute non-identified data via a secure web-based survey system.

Phase I of the project included consultation, establishment of governance, system development, site recruitment and extension to NZ. The current Phase II involves data collection, analysis, evaluation and multi-centre collaboration. AMOSS participation covers over 96% (Australia) and 100% (NZ) births in eligible sites.

The research (NHMRC-funded in Australia) is considered low-risk research, and no consent is required by participants. However, under NHMRC guidelines of research involving fetuses and pregnant women, it was deemed that HREC ethical approval process should be followed(11).

Obtaining approval to collect data involves two stages. Ethical reviews address principles of conduct in health research. Governance reviews address issues related to the individual site’s agreement to participate, including quality, safety, risk management, financial management and accountability(12). Prior to HoMER, ethical and research governance reviews were generally collapsed into one process, with both conducted by the reviewing institution’s
HREC. One of the consequences of HoMER has been the separation of this process, as a ‘site appraisal’ cannot be done by a remote HREC(13).

Participants and recruitment procedure
All maternity units in ANZ with more than 50 births per year were invited to participate in AMOSS using a variety of methods. In Australia, in-principle support was followed by the required application. In NZ, the National Coordinator of its Perinatal and Maternal Mortality Review Committee (PMMRC) worked with all 24 eligible sites (covering 20 District Health Boards [DHBs]) to designate data coordinators.

Data collection method and variables
A purpose-built database was established to manage application processes. Variables included HREC, type/s of applications required, policy variations, history and submission/approval details. Process categories for ethics/research governance were defined along with additional site requirements. A log system recorded communications relating to the review and the length of time from submission by AMOSS to approval by HREC.

Results
There were significant variations in the application processes between NZ and Australia, and additionally by states and territories (Table 2).

Ethics application processes
AMOSS first submitted an ethics application to the University of New South Wales (UNSW) as its administering institution, and approval was granted in March 2009 for a five year period. NSW Population Health and Health Services Research Ethics Committee, accredited to provide single ethical review of research proposals conducted within the New South Wales (NSW) public health system, then approved the AMOSS study in April 2009 for the duration of the research.

The National Ethics Application Form (NEAF) is a key tool in the HoMER system. NEAF is implemented in NSW, Queensland and Victoria, but may also be accepted by HRECs in other States. HRECs in Victoria accepted NEAF and/or Core Module One, with an accompanying Victorian Specific Module which addresses State-specific legislative requirements(14). In Queensland, NEAF and low-risk ethics applications were variously submitted according to how AMOSS was categorised (this system has changed since July 2010 – see below). Victoria and Queensland also had a number of sites that granted approval based on prior ethics approval by local governance committees. Most private hospitals required an ethics review by their own clinical governance committee although two large groups accepted prior HREC approval, followed by site-specific support.

The University of Tasmania, covering all public and private hospitals, endorsed AMOSS under its policy of prior approval from an NHMRC-registered HREC. The Northern Territory gave approval for public hospital sites based on two NEAF applications. In Western Australia, either full hospital-specific and/or country Area Health Service (AHS) ethics applications were required, or it was considered a Quality Activity. The Australian Capital Territory required a NEAF application for each hospital. In South Australia, discussion with a Department of Health representative and Perinatal Practice Workgroup members resulted in state-wide endorsement of AMOSS, followed by site-based e-mail agreements. One SA private hospital additionally required a full ethics application.
Submission processes varied markedly. Hard copy ethics applications were required by 36 HRECs. Of these, 24 HRECs required multiple (range 2-26) hard copies of the application. Over 8,000 printed pages have been required to May 2011. Seven HRECs accepted electronic submission either via email or the Online Forms website(15).

New Zealand

In NZ, AMOSS data is monitored through the AMOSS Working Group under the directive of the Perinatal and Maternal Mortality Review Committee (PMMRC) established under the NZ Public Health and Disability Act 2000. The PMMRC submitted a single application for an Expedited Review of Observational Studies to the National Ethics Advisory Committee (NEAC) and ethical approval AMOSS across all 24 NZ sites was granted until 2014. The entire ethics process required an estimated ten hours(16). Table 2 details the number of application processes according to jurisdiction and HREC within Australia, and compares to NZ and the UK counterpart of AMOSS, the UK Obstetric Surveillance System (UKOSS).

Research governance

The second stage of approval relates to research governance issues, specifically addressing resources, budget and facilities at individual hospitals. Of those 135 HRECs or hospital groups that required a site governance application, five required Site Specific Assessments (SSAs) or other governance application for each hospital, while the remainder requested a single application for all sites, with individual hospitals ratifications. Four sites were uncertain of approval processes due to regional restructuring. Two HRECs required original signatures from six researchers across Australia and the United Kingdom on a previously approved NEAF for the site application.

Variation was significant between but also within HRECs. Staff turnover resulted in policy changes and attendant delays. One application for an SSA application (to an HREC where AMOSS had prior site approval) took 111 days from submission to approval. Additionally, there were large variations in the length of ethics approval granted by HRECs (range nine to 58 months, median 36 months). Separate annual reporting is required by most HRECs and private hospital groups.

Table 1 gives a summary of steps required to complete the AMOSS ethics/governance application process, and comments on the process.

Current status

Ethical/governance approval to participate in AMOSS has been obtained for 261 out of 279 eligible maternity units in Australia and all 24 eligible units in NZ By May 2011, the application process for AMOSS had taken 26 months, an estimated 92 weeks’ person-time and almost 40% of the planned project lifetime. Table 3 details the estimated time involved in completion of the application processes.

Discussion

The review process for AMOSS has hampered much needed national research into severe conditions in pregnancy. The 2007 National Statement on Ethical Conduct in Human Research emphasises the need to eliminate any unnecessary duplicative processes in the conduct of ethical reviews(11). Yet our experience demonstrated this policy was not followed in many instances, with inconsistencies between jurisdictions, AHSs, HRECs and individual
sites perpetuating unnecessary duplication. Figure 2A illustrates the experience of AMOSS in obtaining ethics/governance approval, and contrasts to the NHMRC (Figure 1) model. Figure 2B depicts a suggested model for low-risk multi-centre research.

Kim et al estimate that over half of review board costs are devoted to evaluating low-risk research(17). It is likely that an equivalent cost would apply in the Australian context.

In addition to the resources required by AMOSS project team and investigators, there was an added impost on maternity staff - who spent considerable time undertaking clerical work to progress AMOSS applications - in addition to the HREC staff themselves. This burden is reflected in the increasing numbers of HRECs that charge application-related fees of up to $550: an unnecessary level of cost recovery with true single application processing.

The current processes compromise efficient and successful implementation of public health research without providing a corresponding benefit for research participants. On the contrary, it has been argued that overly regulated ethical review processes on minimal risk research can produce inconsistent decisions and retard quality improvement(17). The degree to which one HREC approach is consistent with others provides a significant indication of effectiveness(18).

A simpler process of ethics/governance approval would allow research such as AMOSS to improve efficiencies and better achieve research objectives. A more centralised system that involves a consistent administrative process as outlined by Fitzgerald and Phillips(19) benefits all research stakeholders. Underpinned by enhanced reciprocities and transparent guidelines, such a system would promote the features that HoMER aims to provide: accountability and efficacy whilst retaining the primacy of protecting research participants.

**Contrasting models of low-risk multi-centre research**

The NZ and UKOSS models provide instructive contrasts in how ethics/governance approval processes for low-risk studies can be streamlined and implemented without risk to patients’ rights and confidentiality.

The single national ethics approval process enabled NZ sites to begin data collection from the beginning of 2010. In contrast, only 38% of Australian sites had completed ethics approval by this stage. The UK Obstetric Surveillance System was launched in 2005(20). Applications for ethics approval of the six initial studies and the system itself (covering approximately 760,000 births) were considered by a single designated research ethics committee. Complete participation by all hospitals with consultant-led maternity units in the UK was achieved within three months of the system launch, and less than a year from commencement of program planning(21). (However, other UK researchers have not found the research governance process as streamlined as UKOSS)(22-24)

Other countries grapple with similar issues as Australia, with varying approaches and policies. A review of research governance processes in Canada found fragmented and uneven approaches(25), with researchers noting that the administrative hurdles required for multi-centre ethical reviews did not contribute toward the protection of research subjects(26). Under a revised policy released 2010, arrangements emphasise stronger reciprocity of reviews(26).

In the USA, the Office for Human Research Protections (OHRP) outlines strategies to avoid duplication in ethics applications for cooperative research. However, the articulation of this policy is uneven and subject to various interpretations(27, 28).

The required steps undertaken by the AMOSS study demonstrates the need for more extensive efficiencies. We welcome the further development of HoMER and its application to
public health research. However, there remains a high level of inconsistency in the implementation of ethical/governance reviews for multi-centre population low-risk research.

**Update on HoMER implementation in Australia**

Changes to the ethics/governance review process in Australia have been steadily implemented over the last few years. Because AMOSS was established during this period of significant reform, and due to the length of time taken to cover the large number of research sites, we have been in a position to monitor the implementation of changes that address some barriers to multi-centre low-risk research.

Key changes to HoMER implemented during AMOSS’ establishment have included:

- Review of all multi-centre research studies conducted in Queensland Health facilities by a single certified HREC since July 2010(29).
- Implementation of modified processes to improve the NSW review of multi-centre research, including a requirement for NSW HRECs to establish an expedited process for low/negligible risk research and benchmarks for timeliness of ethical review and authorisation(30).
- Establishment of a centralised system for single ethical review of multi-centre research in Victoria (currently limited to clinical trials, and not including low-risk population or surveillance studies)(31).
- A discussion paper released late 2010, calling for feedback on good practice in governance in multi-centre human research that has undergone a single ethical review(32).

Whilst reform is evident there is still some way to go before a robust national surveillance system can be established without excessive ethical review duplication.

**Recommendations**

Based on our findings, a number of strategies could significantly reduce the burden on resources whilst maintaining the principles underlying HoMER – efficiency, authority, respect, verifiability and compliance. These suggested measures include:

- Clearer and more transparent guidelines regarding the steps and requirements of ethics and governance applications for both HREC and researchers, such as those introduced by Queensland(29) and outlined in the UK(33).
- Universal acceptance of electronic submissions of ethics applications.
- Simplified site governance endorsements that accept hospital support in electronic (email) format in addition to letters of support and SSAs.
- A single version annual progress/final report circulated to the Lead HREC and research governance offices of participating sites.

**Conclusion**

National public health research is critical to understand the burden of rare, severe maternal morbidity and for the development of evidence-based tools to address these conditions. The information derived from AMOSS, a relatively low resource study, cannot easily be obtained through any other methodology.
However, the ethics/governance review process required by AMOSS resulted in a prolonged setup period of almost two years without any demonstrable benefits to research participants. These application requirements were not aligned to the guidelines and principles of HoMER. The process has been variable and repetitive for researchers, hospitals and ethics review committees alike. The resultant burden on resources challenges the ability of researchers to undertake evidence-based practice in the area of rare, serious obstetric disorders.

The AMOSS project was implemented during a period of considerable change in the way ethics/governance reviews are addressed in Australia. It is hoped that progressive development will achieve the intent and aims of HoMER to provide a significantly more streamlined process than was required by AMOSS. A simplified, uniform approach will greatly enhance project efficiencies. Escalated implementation of a true single ethics review application for multi-centre low-risk research at a national level, together with simplified site governance review processes, is a critical priority.

**Acknowledgements**

Thank you to the obstetricians, midwives, data coordinators, maternity units, risk managers, HREC staff, professional Colleges and others who have supported AMOSS to date with their tireless commitment to helping establish AMOSS and participating in the research.

We gratefully acknowledge NHMRC funding for our research (“The Australasian Maternity Outcomes Surveillance System: improving the safety and quality of maternity care in Australia”; grant number 510298), without which the research would not be possible.
References

<table>
<thead>
<tr>
<th>Steps</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Establish in principle approval from maternity unit and/or clinical/obstetric services</td>
</tr>
<tr>
<td>2</td>
<td>Identify ethics and governance body</td>
</tr>
<tr>
<td>3</td>
<td>Determine the type of research under which AMOSS assessed</td>
</tr>
<tr>
<td>4</td>
<td>Determine the documentation requirements – which forms? How many copies? Electronic only? Hard copy only? Electronic and hard copy? How submitted? Deadlines?</td>
</tr>
<tr>
<td>5</td>
<td>Complete research governance applications</td>
</tr>
<tr>
<td>6</td>
<td>Establish correct personnel to provide site support for governance. Obtain signed site endorsements.</td>
</tr>
<tr>
<td>7</td>
<td>Respond to queries regarding ethics and governance applications</td>
</tr>
<tr>
<td>8</td>
<td>Approval obtained</td>
</tr>
<tr>
<td>9</td>
<td>(Queensland) Submit request for Public Health Act release of data</td>
</tr>
<tr>
<td>10</td>
<td>Annual reporting</td>
</tr>
<tr>
<td>11</td>
<td>Monitor length of ethics approval and re-apply where required</td>
</tr>
</tbody>
</table>
Table 2: AMOSS: ethical and governance review application processes (Australian State jurisdiction and New Zealand), with UK comparison

<table>
<thead>
<tr>
<th></th>
<th>NSW</th>
<th>VIC</th>
<th>QLD</th>
<th>SA</th>
<th>WA</th>
<th>TAS</th>
<th>ACT</th>
<th>NT</th>
<th>Total Australia n=261</th>
<th>Total NZ n=20 District Health Boards (DHBs)</th>
<th>Total UK n= 226</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ethics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>How do we prevent harm to participants?”</td>
<td>2</td>
<td>20</td>
<td>12</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td>n=1</td>
<td>n=1</td>
</tr>
<tr>
<td>Discrete full or expedited applications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- NEAF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (Vic) Module One</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Expedited (low-risk) application</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Full ethics application n=31 Expedited or low risk ethics application n=11</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>n=1</td>
<td>n=1</td>
</tr>
<tr>
<td>Full ethics application</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site Governance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>‘Does the hospital/maternity unit support the research; and does it have the resources?’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site approvals: SSA or hospital governance forms</td>
<td>53</td>
<td>33</td>
<td>24</td>
<td>0</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>n=123</td>
<td>n=1</td>
<td>n=1</td>
</tr>
<tr>
<td>Letters/emails of support</td>
<td>16</td>
<td>33</td>
<td>27</td>
<td>26</td>
<td>28</td>
<td>3</td>
<td>0</td>
<td>4</td>
<td>n=137</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Assessed as Quality Assurance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Monitor, evaluate or improve the quality of health care delivered by a health care provider”</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>n=6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHA Act (Qld only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>‘Is it OK to release the data from the hospital?’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Separate requests to data custodians</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>n=19</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

District Health Boards (DHBs)
Table 3: Resource burden in the ethics/governance application process: June 2009 – October 2010 (with UK comparison)

<table>
<thead>
<tr>
<th>Resource burden - person hours</th>
<th>AUSTRALIA</th>
<th>NEW ZEALAND</th>
<th>UNITED KINGDOM (UK Obstetric Surveillance System UKOSS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMOSS project team</td>
<td>809 logged phone calls; 1,422 logged emails; 1,024 logged miscellaneous notes and communications relating to ethics/governance applications with maternity units and HRECs/governance bodies* (*audited June 2009 – December 2010; does not include time spent by the clinical coordinator for Victoria and Tasmania)</td>
<td>Administrative time spent signing and returning ethics applications.</td>
<td>Time involved in processing ethics applications already processed and approved on other sites</td>
</tr>
<tr>
<td>AMOSS investigators</td>
<td>Time spent responding to AMOSS queries and follow-ups about ethics related applications and issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternity units</td>
<td>Time involved in processing ethics applications already processed and approved on other sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRECs; other ethics and governance bodies</td>
<td>Estimated 2,556 hours January 2009 - December 2010</td>
<td>Total estimated time ten hours (per NZ AMOSS coordinator)</td>
<td>Total estimated ten days (per UK Clinical coordinator)</td>
</tr>
</tbody>
</table>
Figure 1 HoMER concept diagram: Single ethical review

**Single Ethical Review**

- Coordinating Investigator (CI) submits an ethics application to one HREC that is using certified ethical review processes.
- One HREC conducts an ethical review of the research proposal (i.e. single ethical review occurring for one research proposal).
- CI receives the response of one HREC.
- Principal Investigators at each participating institution provide the outcome of the single ethical review to their respective institution.
- Each participating institution uses the outcome of the single ethical review and their site-specific research governance information to determine whether or not research will commence at their institution.

---

**Key**

- Communication flow of ethics and/or research governance information between stakeholders involved in multi-centre research.
Figure 2: Ethics/governance application process

A) AMOSS project

B) A suggested alternate model